{
  "docId": "019dd923-622c-750b-8b99-b43d907adb44",
  "docSlug": "3c210b1fcba7",
  "documentTitle": "Tempus AI, Inc. (TEM)",
  "authorId": "54_Spruce_Point_Capital",
  "authorName": "Spruce Point Capital Management",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2025-05-28 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 37,
  "pageCount": 76,
  "prevPage": 36,
  "nextPage": 38,
  "slideType": "preempt_rebuttal",
  "function": "expose_contradiction",
  "density": "dense",
  "nDataPoints": 3,
  "notes": "The slide uses a table to show the evolution of the AstraZeneca-Tempus agreement over three iterations, emphasizing the lack of meaningful financial growth.",
  "elementsJson": [
    "headline_text",
    "callout_box",
    "data_table",
    "footnote"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b99-b43d907adb44/37",
  "deckHref": "/decks/019dd923-622c-750b-8b99-b43d907adb44",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b99-b43d907adb44.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b99-b43d907adb44#slide-37",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "This decision limited both the overall scale and the strategic upside of the partnership for Tempus, despite the extended timeline and repeated amendments.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd952-fb91-749f-a6b0-5b0a8d59da37",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "metric",
      "text": "AstraZeneca Potential Commitment: $320",
      "attrs": null,
      "subkind": "primary",
      "toolName": "Quantification",
      "toolSlug": "quantification",
      "confidence": null,
      "componentId": "019dd952-fb91-749f-a6b0-5fbb879ea475",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.21,
        "w": 0.96,
        "x": 0.02,
        "y": 0.16
      },
      "kind": "paragraph",
      "text": "The AstraZeneca-Tempus Master Services Agreement (MSA) has now been amended three times. While the duration of the collaboration has been extended by two years, the guaranteed financial commitments from AstraZeneca have increased only modestly-from $200 million to $220 million. Importantly, $100 million of the stated $320 million commitment is not guaranteed. As detailed on the next slide, AstraZeneca also chose to forgo a significant equity option that would have been available had it committed to the additional $100 million under the MC Extension Option prior to December 31, 2024. This decision limited both the overall scale and the strategic upside of the partnership for Tempus, despite the extended timeline and repeated amendments.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0bf36ccf-04e7-404d-a712-10a7dfe186c6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.96,
        "x": 0.02,
        "y": 0.88
      },
      "kind": "source-note",
      "text": "Source: Original MSA between AstraZeneca and Tempus Labs, 1st Amendment, 3rd Amendment. (1) It is agreed and acknowledged that the Financial Commitment for a total amount of $200M [subsequently revised to $220M, unless and until AstraZeneca exercises its option to extend the Financial Commitment for an additional $100M (the “MC Extension Option”). The exercise period for the MC Extension Option will be from the Effective Date to the earlier of (i) December 31, 2024 or (ii) the date that AstraZeneca exercises the Warrant. AstraZeneca will exercise the MC Extension Option either a written notice to Tempus or by exercising the Warrant. If AstraZeneca has not already exercised the MC Extension Option or the Warrant, Tempus will notify AstraZeneca in writing between 90 and 30 days prior to December 31, 2024 that the deadline to exercise the MC Extension Option is approaching.",
      "attrs": {
        "numbered": true
      },
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "dbdede2e-64c7-4fda-95da-17b3c7593279",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.96,
        "x": 0.02,
        "y": 0.38
      },
      "kind": "table",
      "text": "AstraZeneca Collaboration History table showing Original Agreement, 1st Amendment, and 3rd Amendment timelines and potential commitments.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5af85e93-0874-4aae-97e4-a86622b3804f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.45,
        "x": 0.33,
        "y": 0.03
      },
      "kind": "title",
      "text": "AstraZeneca Collaboration And Amendments",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "64a778de-3211-4d2b-a59a-259d364a7f9d",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Action Titles",
      "slug": "action-titles",
      "agent": "Architect",
      "layer": "slide",
      "matchId": "019de87d-f546-770c-87d8-dfe2e05e3e59",
      "evidence": "Title reframes amendments as stagnation",
      "confidence": 80
    },
    {
      "name": "Small Multiples",
      "slug": "small-multiples",
      "agent": "Designer",
      "layer": "slide",
      "matchId": "019de87d-f587-7319-bc26-18da2c1f7b58",
      "evidence": "Three sequential commitment tables",
      "confidence": 80
    }
  ],
  "frameworks": [
    {
      "name": "fraud-exposure",
      "slug": null,
      "matchId": "5808b7b3-f138-445b-80ba-0ec5edb8827d",
      "evidence": "The slide explicitly points out the discrepancy between the public narrative of 'collaboration' and the reality of limited, non-guaranteed financial commitments.",
      "confidence": 0.85
    }
  ],
  "arcBeats": [
    {
      "to": 69,
      "from": 12,
      "beatId": "019de87d-e40d-7574-b4dc-522b102a6735",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Evidence & Proof",
      "beatSlug": null,
      "evidence": "Five evidence sections: insiders, AI hype, partnerships, accounting, billing.",
      "position": 4,
      "confidence": 78,
      "parentBeatName": null,
      "parentBeatSlug": null
    },
    {
      "to": 69,
      "from": 12,
      "beatId": "019de87d-e501-7638-91f7-175bec763c5d",
      "arcName": "The Mountain",
      "arcSlug": "mountain",
      "beatName": "Rising Action",
      "beatSlug": null,
      "evidence": "Mounting evidence across insiders, AI, partnerships, accounting, billing.",
      "position": 2,
      "confidence": 55,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [
    {
      "to": 41,
      "from": 32,
      "name": "Iceberg",
      "slug": "10-iceberg",
      "bestFor": "Consulting, complex problem solving, organizational change",
      "matchId": "019de87d-e60e-7069-8d2e-28f4aad62fde",
      "evidence": "Surface (AZ/GSK/SoftBank deals) vs hidden system (Pathos money cycle, debt covenant pressure).",
      "position": 4,
      "objective": "Show partnerships are surface-level — round-tripping underneath",
      "structure": "The Symptom (Visible) -> The System (Hidden) -> The Root Cause",
      "confidence": 80,
      "description": "Reveal that the visible problem is merely a symptom of a deeper root cause"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}